id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-D-0588-0002,FDA,FDA-2022-D-0588,"Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements- Draft Guidance for Industry",Other,Guidance,2022-05-24T04:00:00Z,2022,5,2022-05-24T04:00:00Z,,2023-10-18T15:52:53Z,,0,0,09000064850def70
FDA-2022-D-0588-0003,FDA,FDA-2022-D-0588,Reference 1 Alternative Procedures for Blood and Blood Components During the COVID-19 Public Health Emergency,Supporting & Related Material,Background Material,2022-05-24T04:00:00Z,2022,5,,,2022-05-24T15:55:26Z,,0,0,09000064850df06b
FDA-2022-D-0588-0001,FDA,FDA-2022-D-0588,"Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements; Draft Guidance for
Industry; Availability",Proposed Rule,Advance Notice of Proposed Rulemaking (ANPRM),2022-05-24T04:00:00Z,2022,5,2022-05-24T04:00:00Z,2022-07-26T03:59:59Z,2023-10-18T18:54:08Z,2022-11120,0,0,09000064850dbdae